Intellectual Property and Process Patent Issues-Patent Reform Act (all provisions).
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription
Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and
follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; issues related to H.R. 942 - American Research and Competitiveness Act of 2011 (112th Congress).
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2012: House of Representatives, U.S. Senate
Bills mentioned
H.R.942: Ensuring Access to Quality Complex Rehabilitation Technology Act of 2013
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q1 Report
Q4 Report
Q3 Report
Registration
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...